A study comparing Tobramycin Inhalation Powder (TIP) administered once daily continuously versus TIP administered BID in 28 day on / 28 day off cycles for the treatment of pulmonary Pseudomonas aeruginosa in patients with cystic fibrosis - Trial 2016-004318-82
Access comprehensive clinical trial information for 2016-004318-82 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals Corporation and is currently status unknown. The study focuses on Cystic Fibrosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2016-004318-82
Trial Details
EU Clinical Trials Register • 2016-004318-82
A study comparing Tobramycin Inhalation Powder (TIP) administered once daily continuously versus TIP administered BID in 28 day on / 28 day off cycles for the treatment of pulmonary Pseudomonas aeruginosa in patients with cystic fibrosis
Study Focus
Sponsor & Location
Novartis Pharmaceuticals Corporation
Timeline & Enrollment
N/A
N/A
N/A
ICD-10 Classifications
Pseudomonas (aeruginosa) as the cause of diseases classified to other chapters
Pneumonia due to Pseudomonas
Congenital pneumonia due to Pseudomonas
Bacterial infection, unspecified
Bacterial infection of unspecified site
Data Source
EU Clinical Trials Register
2016-004318-82
Non-Device Trial